Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Recruiting · NCT03933384 · Interventional (participants receive a specific treatment) · Lead sponsor: Taichung Veterans General Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Who can take part
Age range
20 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients more than 20 years old
- Chronic hepatitis B patients
- Patients who were indicated for hepatitis B virus antiviral therapy
Exclusion criteria
- Decompensated liver disease (Child-Pugh B \&C)
- End stage renal disease (eGRF \< 15 ml/min/1.73m2)
- Prior use of nucleot(s)ide analogues for chronic hepatitis B
- Prior use of interferon for chronic hepatitis B within six months
- Known history of human immunodeficiency virus or hepatitis C virus co-infection
- Concurrent other uncontrolled malignancy
- Women in pregnancy or lactation
- Cannot conform to the study protocol of this study
Where it is running
1 location listed.
- Taichung Veterans General Hospital - Taichung, Taichung, Taiwan